Search

Your search keyword '"Aderka, D"' showing total 306 results
Start Over Author "Aderka, D"
306 results on '"Aderka, D"'

1. Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review

Author

Halpern N, Grinshpun A, Boursi B, Golan T, Margalit O, Aderka D, Friedman E, Laitman Y, Hubert A, Kadouri L, Hamburger T, Barnes-Kedar I, Levi Z, Ben-Aharon I, Brenner B, Goldberg Y, Peretz T, and Shacham-Shmueli E

Subjects
gastric cancer, brca1, brca2, dna damaging agents, parp inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Naama Halpern,1,2 Albert Grinshpun,3 Ben Boursi,1,2 Talia Golan,1,2 Ofer Margalit,1,2 Dan Aderka,1,2 Eitan Friedman,2,4 Yael Laitman,2,3 Ayala Hubert,3 Luna Kadouri,3 Tamar Hamburger,3 Inbal Barnes-Kedar,2,5 Zohar Levi,2,6 Irit Ben-Aharon,2,7 Baruch Brenner,2,7 Yael Goldberg,2,5 Tamar Peretz,3 Einat Shacham-Shmueli1,2 1Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel; 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; 4The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel-Hashomer, Israel; 5Recanati Genetics Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel; 6Division of Gastroenterology, Rabin Medical Center, Early Detection and High Risk Unit, Petach Tikva, Israel; 7Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva, IsraelCorrespondence: Naama HalpernDepartment of Oncology, Sheba Medical Center, Tel-Hashomer, Rmat Gan, IsraelTel +972-3-530-2668Fax +972-3-5304958Email naama.halpern@sheba.gov.ilBackground: The prognosis of gastric cancer (GC) is poor with a median overall survival (OS) of less than 12 months in advanced-stage disease. The search for distinct genetic subgroups of GC patients and predictive biomarkers is ongoing. While BRCA1 or BRCA2 germline mutations (gBRCAm) have potential therapeutic implications in ovarian, breast and pancreatic cancers, their significance in GC patients has not been established.Patients and Methods: A retrospective multi-center data analysis of GC patients with gBRCAm was conducted, detailing the clinical characteristics and disease course in this unique subset of patients.Results: Ten GC patients with gBRCAm were identified, six of them with metastatic disease. The median OS of all ten GC patients was 47.5 (13– 192) months. Median OS for patients diagnosed with operable disease was 55.5 (13– 192) months and of the patients with metastatic disease (calculated from metastatic disease diagnosis) 32 (15– 52) months with an exceptional 1-, 2- and 3-year survival rate of 100%, 83.3% and 50%, respectively.Conclusion: These preliminary data suggest that gBRCAm in GC patients are associated with a favorable prognosis. Furthermore, gBRCAm might be a predictive biomarker to DNA-damaging agents response in GC patients, similarly to its established role in other malignancies. Further research is needed to confirm our findings.Keywords: gastric cancer, BRCA1, BRCA2, DNA-damaging agents, PARP inhibitors

Published
2020

2. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

Author

Stintzing, S., Wirapati, P., Lenz, H.-J., Neureiter, D., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Al-Batran, S., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Moehler, M., Scheithauer, W., Held, S., Modest, D.P., Jung, A., Kirchner, T., Aderka, D., Tejpar, S., and Heinemann, V.

Published
2019
Full Text
View/download PDF

3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Author

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., and Arnold, D.

Published
2016
Full Text
View/download PDF

4. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Author

Schmoll, H.J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C.J., Balmana, J., Regula, J., Nagtegaal, I.D., Beets-Tan, R.G., Arnold, D., Ciardiello, F., Hoff, P., Kerr, D., Köhne, C.H., Labianca, R., Price, T., Scheithauer, W., Sobrero, A., Tabernero, J., Aderka, D., Barroso, S., Bodoky, G., Douillard, J.Y., El Ghazaly, H., Gallardo, J., Garin, A., Glynne-Jones, R., Jordan, K., Meshcheryakov, A., Papamichail, D., Pfeiffer, P., Souglakos, I., Turhal, S., and Cervantes, A.

Published
2012
Full Text
View/download PDF

7. SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC

Author

Aderka, D., primary, Kopetz, S., additional, Grothey, A., additional, Van Cutsem, E., additional, Yaeger, R., additional, Wasan, H., additional, Yoshino, T., additional, Desai, J., additional, Ciardiello, F., additional, Golden, A., additional, Edwards, M., additional, and Tabernero, J., additional

Published
2021
Full Text
View/download PDF

12. Nuclear Export Inhibition for Radiosensitization; a Proof-of-Concept Phase I Clinical Trial of Neoadjuvant KPT-330 Plus Chemoradiation in Locally Advanced Rectal Cancer

Author

Lawrence, Y., primary, Shmueli, E., additional, Yarom, N., additional, Khaikin, M., additional, Venturero, M., additional, Apter, S., additional, Inbar, Y., additional, Aderka, D., additional, Halpern, N., additional, Berger, R., additional, Shani, A., additional, Schvimer, M., additional, Raskin, S., additional, Ackerstein, A., additional, Rashal, T., additional, Symon, Z., additional, and Golan, T., additional

Published
2018
Full Text
View/download PDF

14. Prolonged overall survival of metastatic gastric cancer patients with BRCA germline mutations

Author

Halpern, N., primary, Grinshpun, A., additional, Boursi, B., additional, Golan, T., additional, Margalit, O., additional, Aderka, D., additional, Laitman, Y., additional, Friedman, E., additional, Hubert, A., additional, Peretz, T., additional, Hamburger, T., additional, Kedar-Barnes, I., additional, Levi, Z., additional, Ben-Aharon, I., additional, Goldberg, Y., additional, and Shacham-Shmueli, E., additional

Published
2018
Full Text
View/download PDF

18. 117. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal surface malignancies in the elderly

Author

Dux, J., primary, Rayman, S., additional, Zendel, A., additional, Segev, L., additional, Hoffman, A., additional, Ben Yaacov, A., additional, Marom, G., additional, Aderka, D., additional, Shacham Shmueli, E., additional, Beny, A., additional, Ayala, H., additional, Grenader, T., additional, Brenner, B., additional, Purim, O., additional, Gutman, M., additional, Venturero, M., additional, and Nissan, A., additional

Published
2016
Full Text
View/download PDF

19. 709. Metastases to surgical scars from primary operation for intraabdominal malignancies, revisited during secondary cytoreductive surgery for recurrent peritoneal disease

Author

Dux, J., primary, Rayman, S., additional, Shachar, Y., additional, Adileh, M., additional, Shapiro, R., additional, Zippel, D., additional, Ben-Yaakov, A., additional, Shacham-Shmueli, E., additional, Aderka, D., additional, Venturero, M., additional, and Nissan, A., additional

Published
2016
Full Text
View/download PDF

25. Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF

Author

Andrew Cope, Aderka D, Wallach D, Kahan M, Nr, Chu, Fm, Brennan, and Feldmann M

Subjects
musculoskeletal diseases, Tumor Necrosis Factor-alpha, T-Lymphocytes, Down-Regulation, Flow Cytometry, Lymphocyte Activation, Receptors, Tumor Necrosis Factor, Clone Cells, Kinetics, T-Lymphocyte Subsets, Humans, Tetradecanoylphorbol Acetate, Research Article, Muromonab-CD3
Abstract

Soluble tumour necrosis factor receptors (sTNF-R) are up-regulated at sites of chronic inflammation such as rheumatoid synovial joints. The p75 sTNF-R is the more abundant, suggesting an important role for this TNF inhibitor in regulating TNF bioactivity in vivo. As the precise cellular source of these soluble receptors is not known, we investigated the production and regulation of sTNF-R by T lymphocytes, an abundant cell type in inflammatory infiltrates, which upon activation express high levels of p75 surface receptors. Using panels of T-cell lines and clones expressing high levels of p75 TNF-R, we found that p75 sTNF-R production upon stimulation is a feature common to all subsets of T cells, including cells of the CD4-CD8- double negative phenotype expressing either alpha beta or gamma delta T-cell receptors (TCR). In contrast, levels of p55 sTNF-R were only detected when T cells were stimulated at higher densities and by potent mitogens such as phorbol 12-myristate 13-acetate (PMA). Detailed kinetic analyses revealed that the production of p75 sTNF-R was biphasic, the first phase was activation dependent, occurring in the absence of detectable TNF, while the second phase of p75 sTNF-R production was regulated by cytokines such as TNF. Unlike short-term exposure to TNF which enhances sTNF-R production in vitro and in vivo, prolonged exposure of T lymphocytes to TNF suppressed p75 sTNF-R (but not p55 sTNF-R) production in a dose- and time-dependent fashion. These results suggest that in patients with chronic inflammatory disease, which are exposed to augmented levels of bioactive TNF for prolonged periods, the production of p75 sTNF-R may be impaired.

Published
1995

27. 2133

Author

Symon, Z., primary, Rabin, T., additional, Levin, D., additional, Menhel, J., additional, Alezra, D., additional, Lawrence, T.S., additional, Aderka, D., additional, Wolf, I., additional, Catane, R., additional, and Pfeffer, M.R., additional

Published
2006
Full Text
View/download PDF

39. Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF.

Author

Cope, A. P., Aderka, D., Wallach, D., Kahan, M., Chu, N. R., Brennan, F. M., and Feldmann, M.

Subjects
*TUMOR necrosis factors, *T cells, *INFLAMMATION, *JOINTS (Anatomy), *CHEMICAL inhibitors, *GENETICS
Abstract

Soluble tumour necrosis factor receptors (sTNF-R) are up-regulated at sites of chronic inflammation such as rheumatoid synovial joints. The p75 sTNF-R is the more abundant, suggesting an important role for this TNF inhibitor in regulating TNF bioactivity in vivo. As the precise cellular source of these soluble receptors is not known, we investigated the production and regulation of sTNF-R by T lymphocytes, an abundant cell type in inflammatory infiltrates, which upon activation express high levels of p75 surface receptors. Using panels of T-cell lines and clones expressing high levels of p75 TNF-R, we found that p75 sTNF-R production upon stimulation is a feature common to all subsets of T cells, including cells of the CD4- CD8- double negative phenotype expressing either αβ or γδ T-cell receptors (TCR). In contrast, levels of p55 sTNF-R were only detected when T cells were stimulated at higher densities and by potent mitogens such as phorbol 12-myristate 13-acetate (PMA). Detailed kinetic analyses revealed that the production of p75 sTNF-R was biphasic, the first phase was activation dependent, occurring in the absence of detectable TNF, while the second phase of p75 sTNF-R production was regulated by cytokines such as TNF. Unlike short-term exposure to TNF which enhances sTNF-R production in vitro and in vivo, prolonged exposure oft lymphocytes to TNF suppressed p75 sTNF-R (but not p55 sTNFR) production in a dose- and time-dependent fashion. These results suggest that in patients with chronic inflammatory disease, which are exposed to augmented levels of bioactive TNF for prolonged periods, the production of p75 sTNF-R may be impaired. [ABSTRACT FROM AUTHOR]

Published
1995

50. Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein.

Author

Hahn, T, Toker, L, Budilovsky, S, Aderka, D, Eshhar, Z, and Wallach, D

Abstract

Crude preparations of cytotoxins (CTXs) produced by human peripheral blood mononuclear cells exert a marked cytotoxic effect when applied to cells in the presence of cycloheximide but in its absence can induce resistance to cytotoxicity. To examine the relationship between these cytotoxic and protective activities, we attempted to fully dissociate the CTX from the other proteins secreted by mononuclear cells. Mice injected with preparations of the cytokines secreted by peripheral blood mononuclear cells developed significant titers of serum antibodies to CTX(s). Splenocytes of such immunized mice were fused with NSO myeloma cells; a few among the resulting hybridoma cells secreted CTX-binding antibodies. Immunoadsorbents constructed with a monoclonal antibody produced by one of these hybridomas were used to purify to homogeneity a CTX (Mr approximately 17,500) from crude preparations of cytokines, by a single adsorption and elution cycle. Purified CTX was cytotoxic in the presence of cycloheximide but in its absence induced resistance to cytotoxicity; this resistance was manifested by decreased vulnerability to CTX in a subsequent incubation in the presence of cycloheximide. We conclude that CTX itself can induce certain changes in cells, which are reflected in resistance to its own cytotoxic effect.

Published
1985
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results